Clinical trial · Observational
Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants
Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer
NCT00628654CI-TRIAL-00036345completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: New diagnostic procedures, such as glycan analysis, may be effective in finding ovarian epithelial cancer. PURPOSE: This clinical trial is studying how well glycan analysis works in diagnosing cancer in women with ovarian epithelial cancer and in healthy female participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Volunteers
- description
- Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
- label
- Patients with cancer
- description
- Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
Primary outcomes (1)
- measure
- Accuracy of glycan analysis
- timeFrame
- one time for healthy volunteers; up to 2 years for patients with cancer
- description
- For healthy controls, a single sample will be obtained. For patients scheduled for surgery, two samples will be obtained: one preoperatively and one postoperatively. Ovarian cancer patients who agree to participate in the longitudinal study will have follow-up serum samples drawn periodically during chemotherapy treatments and then during surveillance visits, to correspond with routine blood testing for CA 125. They will be asked to participate for 2 years, with a maximum of 8 blood draws per year (to be coordinated with other venipunctures, if possible).
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Able to understand consent document for participation in the study * Not pregnant * Negative pregnancy test Participants must meet 1 of the following criteria: * Patients scheduled for ovarian surgery for an ovarian mass * Healthy female volunteers with no active cancer or history of cancer
References
Publications (0)
Data not yet available
No reference posted for this study.